Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02050919 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
A Phase 2 study of Pleomorphic Rhabdomyosarcoma and Stage III Adult Soft Tissue Sarcoma AJCC v7, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02050919 is a Phase 2 study of Pleomorphic Rhabdomyosarcoma and Stage III Adult Soft Tissue Sarcoma AJCC v7 that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02050919, a Phase 2 study of Pleomorphic Rhabdomyosarcoma and Stage III Adult Soft Tissue Sarcoma AJCC v7, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery work in treating patients with high-risk stage IIB-IV soft tissue sarcoma. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin hydrochloride and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery may be an effective treatment for soft tissue sarcoma.
Conditions Studied
Interventions
- RADIATION External Beam Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- DRUG Ifosfamide
- DRUG Sorafenib Tosylate
- DRUG Epirubicin Hydrochloride
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02050919
The ClinicalTrials.gov registry entry for NCT02050919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pleomorphic Rhabdomyosarcoma appearing as the primary indexed condition, and to 5 interventions - of which External Beam Radiation Therapy is the first listed.
NCT02050919 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02050919 about?
NCT02050919 is a clinical study titled "Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma". This phase II trial studies how well sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery work in treating patients with high-risk stage IIB-IV soft tissue sarcoma. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. D...
What is the current status of trial NCT02050919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-12-03. Estimated completion is 2020-12-31.
What conditions does trial NCT02050919 study?
This clinical trial studies the following conditions: Pleomorphic Rhabdomyosarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7.
What interventions are being tested in trial NCT02050919?
The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Ifosfamide (DRUG), Sorafenib Tosylate (DRUG), Epirubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02050919?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02050919 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleomorphic Rhabdomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Pleomorphic Rhabdomyosarcoma
All registered trials for this condition
Stage III Adult Soft Tissue Sarcoma AJCC v7
All registered trials for this condition
Oregon
All trials with a study site in Oregon
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.